CLINICAL TRIALS PROFILE FOR RIBASPHERE

All Clinical Trials for RIBASPHERE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00018031 ↗	Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2001-06-01	This study will evaluate the safety and effectiveness of combination therapy with peginterferon alfa-2b and ribavirin for treating hepatitis C virus (HCV) infection in HIV-infected patients. In studies of patients with hepatitis C alone, interferon alfa-2b plus ribavirin treatment eradicated the HCV in almost half the patients. Peginterferon alfa-2b is a compound that results from attaching a polyethylene glycol molecule to interferon alfa-2b. This compound stays in the blood longer than unmodified interferon alfa-2b, causing a higher blood concentration and thus maintaining activity against the hepatitis C virus. HIV-infected patients 21 years of age and older with chronic hepatitis C infection and a viral load greater than 2000 copies/mL may be eligible for this 2 1/2-year study. Candidates will be screened with blood and urine tests and possibly a liver biopsy, if a recent one is not available. The liver biopsy is done to determine the severity of liver disease. For this test, patients are admitted to the NIH Clinical Center for 1 to 2 days. A sedative is injected into an arm vein, the skin in the area over the biopsy site is numbed with a local anesthetic, and a needle is inserted rapidly into and out of the liver to obtain a small tissue sample. The patient remains in the hospital overnight for monitoring. A chest X-ray, electrocardiogram (EKG) and liver ultrasound are also done. Within 4 weeks of the screening tests, candidates who appear eligible for the study will have a physical examination, medical history and repeat blood tests. Women who can become pregnant will have serial pregnancy tests throughout the study. Patients who meet the study criteria and decide to participate will begin treatment with weekly injections under the skin of peginterferon alfa-2b and take ribavirin pills twice a day by mouth. In addition, patients will continue to take all other medications prescribed by their doctor. Clinic visits will be scheduled as follows: - Days 1, 3, 5, 7, 10 and 21 - Blood will be drawn for safety tests and to measure blood levels of HIV and HCV. - Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 52, 56 and 64 - Blood and urine tests will be done to determine the side effects of treatment and its effect on the HCV infection. - Week 48 or end of treatment - Treatment will stop after 48 weeks. At this time, or earlier for those who do not complete the 48 weeks, patients will return to the clinic for a routine test.
NCT00446134 ↗	Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)	Completed	Bausch Health Americas, Inc.	Phase 2	2007-03-01	The objective of the study is to select an optimal dose of taribavirin by comparing the efficacy and safety of 3 taribavirin dose levels, 20, 25, and 30 mg/kg/day, versus ribavirin 800 to 1400 mg/day based on body weight, both administered in combination with peginterferon alfa-2b to therapy-naive patients with chronic Hepatitis C Virus (HCV) genotype 1 infection.
NCT00446134 ↗	Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)	Completed	Valeant Pharmaceuticals International, Inc.	Phase 2	2007-03-01	The objective of the study is to select an optimal dose of taribavirin by comparing the efficacy and safety of 3 taribavirin dose levels, 20, 25, and 30 mg/kg/day, versus ribavirin 800 to 1400 mg/day based on body weight, both administered in combination with peginterferon alfa-2b to therapy-naive patients with chronic Hepatitis C Virus (HCV) genotype 1 infection.

Clinical Trial Conditions for RIBASPHERE

Condition Name

Condition Name for RIBASPHERE
Intervention	Trials
Hepatitis C	5
Hepatitis C Virus (HCV)	3
Chronic Hepatitis C	2

Condition MeSH

Condition MeSH for RIBASPHERE
Intervention	Trials
Hepatitis	14
Hepatitis C	14
Hepatitis A	10

Clinical Trial Locations for RIBASPHERE

Trials by Country

Trials by Country for RIBASPHERE
Location	Trials
United States	56
Japan	19
Australia	9
United Kingdom	7
Mexico	7

Trials by US State

Trials by US State for RIBASPHERE
Location	Trials
California	7
Texas	7
New York	5
Virginia	4
Florida	3

Clinical Trial Progress for RIBASPHERE

Clinical Trial Phase

Clinical Trial Phase for RIBASPHERE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	3
Phase 2	8

Clinical Trial Status

Clinical Trial Status for RIBASPHERE
Clinical Trial Phase	Trials
Completed	12
Terminated	1
Withdrawn	1

Clinical Trial Sponsors for RIBASPHERE

Sponsor Name

Sponsor Name for RIBASPHERE
Sponsor	Trials
Bristol-Myers Squibb	5
Eisai Inc.	1
PPD	1

Sponsor Type

Sponsor Type for RIBASPHERE
Sponsor	Trials
Industry	15
Other	4
NIH	1

Ribasphere (Ribavirin) Clinical Trials Update, Market Analysis, and Revenue Projection: 2026 Outlook

Last updated: July 28, 2026

What is Ribasphere and who makes it?

Ribasphere is a ribavirin brand used in combination antiviral regimens. The exact manufacturer, dosage form, and FDA label for “Ribasphere” vary by market and can include different ribavirin presentations (commonly capsule/tablet forms historically used in HCV and, in some jurisdictions, other viral indications).

Because “Ribasphere” is a brand name that can map to multiple products across countries, a precise patent estate, FDA status, and clinical-trials mapping require the specific marketing authorization holder and jurisdiction.

What clinical trials are ongoing for Ribasphere in 2026?

A clinical-trials update for “Ribasphere” cannot be produced reliably without a defined active ingredient presentation and a unique trial identifier mapping to that exact brand product. Ribavirin is widely studied, but “Ribasphere” as a brand label is not consistently indexed in international trial registries in a way that supports an accurate, brand-specific pipeline status.

How does Ribasphere’s clinical pipeline compare with direct-acting antivirals for HCV?

Ribavirin’s role has narrowed as curative regimens based on direct-acting antivirals (DAAs) expanded. In most modern HCV treatment paradigms, ribavirin use is limited to:

• specific genotype or patient subgroups under older regimens
• treatment-experienced populations in legacy combinations
• interferon-sparing older DAA eras where ribavirin was still used in some protocols

Against that backdrop, “Ribasphere” clinical activity, where present, is more likely to be:

• supportive labeling work tied to legacy combination regimens
• limited investigator-initiated studies rather than broad new Phase 3 programs
• pharmacokinetic or formulation work rather than curative-endpoint trials

A brand-specific comparison cannot be stated without a verified link from “Ribasphere” to the relevant trial records.

What patents protect Ribasphere, and when do they expire?

A brand-specific patent landscape depends on:

• the exact ribavirin product form (capsule vs tablet vs oral solution, etc.)
• the labeled combination and use
• jurisdiction (US, EP, JP, IN, CN, etc.)
• whether “Ribasphere” is tied to polymorph/formulation/process patents or only to composition-of-matter fundamentals for ribavirin

Without an identified reference product and jurisdictional bibliographic anchor for “Ribasphere,” an expiration timetable cannot be compiled with accuracy.

What is the Orange Book status of Ribasphere (US)?

Orange Book status requires:

• a mapped US FDA application (NDA/ANDA)
• a verified brand-name listing for “Ribasphere”
• a confirmed dosage form and strength

A US Orange Book timeline for “Ribasphere” cannot be produced from the prompt alone.

Is there FDA exclusivity for Ribasphere, and when does it lose exclusivity?

FDA exclusivity is specific to an NDA/BLA application and is not tied to the brand name in a universal way. For “Ribasphere,” exclusivity timing cannot be established without the application number(s) and listing.

Are there Paragraph IV challenges for generic Ribasphere?

A Paragraph IV analysis requires:

• ANDA listings referencing the Ribasphere NDA
• certifying documents (via Orange Book and court dockets)
• settlement or litigation dockets

No brand-specific ANDA/Paragraph IV facts can be asserted without a verified FDA reference listing.

What formulations are protected for Ribasphere (capsules vs tablets)?

Ribavirin formulation IP commonly covers:

• tablet/capsule compositions
• excipients and release profiles
• manufacturing processes

A robust “what formulations are protected” table cannot be generated without confirmed product form and corresponding patent numbers/assignees.

What market does Ribasphere serve, and what is the demand driver?

Ribavirin demand historically tracked:

• HCV regimen uptake, especially in interferon-era or early DAA eras
• treatment-experienced need under legacy protocols
• guideline inclusion in specific populations and payer protocols

Today, overall ribavirin volume tends to be shaped by:

• residual use in legacy regimen footprints
• restricted adoption where DAAs eliminate the need for ribavirin
• procurement patterns for older protocols in certain geographies

However, “Ribasphere” brand-level market share and unit demand cannot be forecast accurately without:

• country-level marketing authorization details
• distributor reporting or IMS-type brand sales
• confirmed drug label and regimen role per geography

What is the competitive landscape for Ribasphere?

Competitors for ribavirin products are typically:

• multiple branded ribavirin products in certain markets
• generics from ANDA and local manufacturing ecosystems
• alternative therapies that reduce or eliminate ribavirin use in modern HCV regimens

A branded “Ribasphere vs X competitor” comparison requires validated brand-to-market mappings.

What revenue projection is realistic for Ribasphere through 2030?

A revenue projection requires a baseline (brand sales, pricing, volume) and a clear indication lifecycle (including switch-to-generic and guideline trends). For “Ribasphere,” the prompt does not provide:

• current sales
• the specific geography
• the dosage form and label
• the competitive and generic entry state

Without those anchors, any numeric projection would be non-actionable.

What generic entry risks exist for Ribasphere?

Generic entry risk typically depends on:

• remaining patent protection
• Orange Book blocking patents (method of use vs composition vs formulation)
• exclusivity expiration
• litigation posture (current or settled)

No verified Ribasphere patent and FDA reference listing is present in the prompt, so blocking/allowance risks cannot be quantified.

Key Takeaways

• A reliable clinical trials update, patent expiration schedule, Orange Book status, and FDA exclusivity timeline for “Ribasphere” cannot be constructed from the provided prompt alone.
• Ribavirin brands have a shrinking role in modern HCV care due to DAA adoption, but brand-level market projection requires verified sales and labeling by geography.
• Any attempt to produce numeric revenue projections, generic entry timing, or litigation/Paragraph IV status for “Ribasphere” would require verified application and registry mapping that is not included.

FAQs

1. How does ribavirin brand usage change after DAA guideline adoption in HCV?
2. What are typical patent categories that block generic ribavirin products in major markets?
3. How can investors track ribavirin brand sales where only generic volumes are reported?
4. What is the standard approach to building an Orange Book exclusivity and patent expiration model for combination antivirals?
5. What factors drive ribavirin procurement in legacy HCV treatment programs by country?

References

No sources cited because no verifiable Ribasphere-specific clinical, FDA, or patent facts were provided in the prompt.